Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and relationship with haemoglobin and serum iron

Stefanie Howaldt¹, Ian Jacob², Mark Sampson³, Fatma Akriche⁴

¹MZV für Immunologie, Hamburg, Germany; ²Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom; ³Shield Therapeutics PLC, London, United Kingdom; ⁴Norgine Ltd, Rueil Malmaison, France.

Background

Iron deficiency anaemia (IDA) is common in patients with inflammatory bowel disease (IBD). Symptoms include fatigue, dyspepsia, palpitations and headache, and can significantly impair health-related quality of life (HRQoL) over and above the impact of the underlying disease.¹,² IV iron is currently the main treatment for patients intolerant or unsuitable for standard oral iron.³ Due to the risk of hypersensitivity reactions, it must be administered in a setting with full resuscitation facilities.³ Intolerance to oral iron is common due to oxidation of unabsorbed ferrous (Fe²⁺) iron and consequent damage to the gastrointestinal tract from reactive oxygen species.⁴ Ferric maltol (FM), a stable oral complex of ferric (Fe³⁺) iron and maltol, is designed to provide efficient iron delivery and minimise formation of free iron in the gut, thus reducing the potential for gastric adverse effects.⁵ It is approved in the EU for the treatment of iron deficiency in adults.⁶

The HRQoL benefits of FM and IV ferric carboxymaltose (FCM) and their relationship to haematological parameters were evaluated in an exploratory post hoc analysis using data from a randomised controlled trial (NCT02680756)⁷.

Trial design and primary findings

Patients with IBD and IDA (haemoglobin [Hb] ≥8.0 g/dL and <11.0 g/dL; for women ≥8.0 g/dL and ≤12.0 g/dL for men; and ferritin <30 ng/mL or ferritin <100 ng/mL with transferrin saturation <20%) were randomised to FM (30 mg b.d.) or IV FCM (as per local guidelines for the treatment of iron deficiency in IBD). Patients were randomised: 125 to FM (per-protocol [PP] n=86) and 125 to IV FCM (PP n=92). The primary endpoint was Hb responder rate (proportion of patients achieving a ≥2 g/dL increase or normalisation of Hb at week 12). HRQoL was assessed via the Short Form Health Survey (SF-36).

- 250 patients were randomised: 125 to FM (per-protocol [PP] n=86) and 125 to IV FCM (PP n=92).
- The Hb responder rate for oral FM was non-inferior to IV FCM in the PP population (74% vs 83%; risk difference was -0.1 (two-sided p=0.017; 95% CI -0.2, 0.0)), with the pre-defined non-inferiority margin of 20% difference.

Methods

Analysis of HRQoL and haematological parameters

In a post hoc analysis of patient-level data, Hb, serum iron, serum ferritin and SF-36 scores (physical component summary [PCS], mental component summary [MCS]) and individual domain scores were analysed at baseline and week 12. Correlations between SF-36 scores (PCS and MCS) and haematological parameters were assessed via Pearson’s correlation coefficient (PCC) using pooled data from the FM and IV FCM treatment arms. Change from baseline in SF-36 scores and correlations between parameters were summarised graphically and descriptively. SF-36 domain score data was included for all patients who had data within the required time windows (FM: N=109; IV FCM: N=114).

Results

HRQoL and clinical parameter improvements

- Hb, serum iron, serum ferritin and HRQoL all improved with both treatments at Week 12.
- Improvements in SF-36 PCS and MCS scores were slightly greater with FM than with IV FCM (difference not statistically significant; Table 1).
- Scores improved across all SF-36 domains for both FM and IV FCM (Figure 1).

Correlations between HRQoL and clinical parameters

Improvements in Hb and serum iron were positively associated with improvements in HRQoL (PCS and MCS; Table 2; Figure 2).

Table 1: Change in PCS and MCS scores from baseline to week 12

<table>
<thead>
<tr>
<th></th>
<th>Oral FM</th>
<th>IV FCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCS</td>
<td>+3.23</td>
<td>+2.09</td>
</tr>
<tr>
<td>p-value</td>
<td>0.022</td>
<td>0.027</td>
</tr>
<tr>
<td>MCS</td>
<td>+3.89</td>
<td>+2.52</td>
</tr>
</tbody>
</table>

Table 2: Correlations between HRQoL (PCS and MCS), Hb and serum iron

<table>
<thead>
<tr>
<th>Correlation with Hb*</th>
<th>Correlation with serum iron*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCS</td>
</tr>
<tr>
<td>Oral/FM and IV FCM</td>
<td>0.227</td>
</tr>
</tbody>
</table>

*Correlations assessed via PCC, FM and IV FCM pooled data

Conclusions

- HRQoL as measured by SF-36 PCS and MCS improved following both FM and IV FCM, with no statistically significant difference between treatments. Improvements were positively correlated with increases in Hb and serum iron.
- Patient-reported outcomes are an important way to measure health and wellbeing. Measures of HRQoL in IAD may have the potential to reflect both IDA symptoms and treatment-related issues such as adverse effects, so are a useful tool to capture additional treatment benefits beyond those typically reported in clinical studies.
- HRQoL is thus an important measure of treatment effectiveness when paired with clinical outcomes, from both a patient and decision-making perspective.
- FM provides HRQoL benefits at least as great as those with IV FCM, and may provide an oral alternative to IV iron in patients with IBD.